1xbet모바일 Pharmaceutical Co., Ltd.

Pharmaceuticals

March 10, 2011

1xbet모바일 Pharmaceutical Received Approval for Additional Indication of L-Cartin^®tablets 1xbet모바일 Carnitine Deficiency in Japan

Tokyo, Japan, March 10, 2011 -- 1xbet모바일 Pharmaceutical Co., Ltd. today announced that it received an approval for Additional Indication of L-Cartin^®tablets (nonproprietary name: levocarnitine chloride) 1xbet모바일 carnitine deficiency.

Latest Pharmaceutical Bus1xbet모바일ess related News Releases

30 SEP 2024

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet모바일 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved 1xbet모바일 Japan -

24 SEP 2024

1xbet모바일 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment 1xbet모바일 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet 보너스 코드

1xbet모바일 Receives Approval in Japan for Lupkynis^®as a Treatment 1xbet모바일 Lupus Nephritis

News Releases | Otsuka

1xbet모바일 Pharmaceutical Co., Ltd.

1xbet모바일 Pharmaceutical Received Approval for Additional Indication of L-Cartin®tablets 1xbet모바일 Carnitine Deficiency in Japan

HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet모바일 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight®hematological malignancies gene panel test approved 1xbet모바일 Japan -

1xbet모바일 Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment 1xbet모바일 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet모바일 Receives Approval in Japan for Lupkynis®as a Treatment 1xbet모바일 Lupus Nephritis

1xbet모바일 Pharmaceutical Received Approval for Additional Indication of L-Cartin^®tablets 1xbet모바일 Carnitine Deficiency in Japan

HemeSight^®, the First-in-Japan Comprehensive Genomic Profiling Assay 1xbet모바일 Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight^®hematological malignancies gene panel test approved 1xbet모바일 Japan -

1xbet모바일 Obtains Additional Indication for Rexulti^®in Japan as an Adjunctive Treatment 1xbet모바일 Agitation Associated with Dementia due to Alzheimer's Disease

1xbet모바일 Receives Approval in Japan for Lupkynis^®as a Treatment 1xbet모바일 Lupus Nephritis